SynAging is a contract research organization (CRO),
providing new insights and disease-related understanding of drug candidates (small molecules and biopharmaceuticals), nutraceuticals, and other active substances, activity by deploying neurodegenerative disease models.
- In vitro services
Investigating single to hundreds of test candidates in primary rodent neurons, human neurons and neuronal cell lines.
- In vivo services
Investigating test items in validated behavioral paradigms using acutely induced neurodegenerative rodent models.
- Ex vivo services
Quantification of synaptic and neuroinflammatory markers by ELISA or immune histochemistry before and after treatment
SynAging maintains long-term strategic research collaborations for target validation and drug discovery for neurodegenerative diseases.
SynAging’s service team has more than 100 years of combined experience in the field of neurodegenerative disease research. Key staff has published more than 50 peer-reviewed publications.
Providing clients with misfolded-protein-aggregate-induced phenotypic models in wild type systems to model sporadic neurodegenerative diseases, accelerating drug discovery of symptomatic and disease-modifying therapeutics.